“Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes”

“MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — Geron Corporation (GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

‘The start of the Phase 3 portion of IMerge is a significant milestone for Geron and imetelstat,’ said John A. Scarlett, M.D., Chairman and Chief Executive Officer. ‘We are hopeful that the Phase 3 will confirm the encouraging results from the Phase 2 portion, and that imetelstat could become a much-needed treatment alternative for patients with lower risk MDS.’ ”